Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2023 | 26 | 3.020 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 18 | 1.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2021 | 21 | 1.420 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 32 | 1.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2021 | 67 | 1.090 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 15 | 0.990 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 9 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 364 | 0.900 |
Why?
|
| Databases, Factual | 2 | 2022 | 251 | 0.870 |
Why?
|
| Leukemia, B-Cell | 1 | 2021 | 3 | 0.760 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 18 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 3 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 40 | 0.690 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 67 | 0.680 |
Why?
|
| Alkylating Agents | 1 | 2019 | 7 | 0.660 |
Why?
|
| Myeloproliferative Disorders | 1 | 2019 | 11 | 0.650 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 21 | 0.650 |
Why?
|
| Humans | 19 | 2024 | 26773 | 0.510 |
Why?
|
| Vincristine | 2 | 2021 | 9 | 0.370 |
Why?
|
| Prednisone | 2 | 2021 | 51 | 0.360 |
Why?
|
| Cyclophosphamide | 2 | 2021 | 36 | 0.360 |
Why?
|
| Doxorubicin | 2 | 2021 | 74 | 0.360 |
Why?
|
| Aged | 4 | 2023 | 5157 | 0.340 |
Why?
|
| Young Adult | 2 | 2023 | 2578 | 0.260 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 290 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 74 | 0.230 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 98 | 0.210 |
Why?
|
| SEER Program | 1 | 2023 | 46 | 0.210 |
Why?
|
| Minority Groups | 1 | 2023 | 62 | 0.210 |
Why?
|
| Pericarditis | 1 | 2022 | 14 | 0.210 |
Why?
|
| Recurrence | 2 | 2020 | 315 | 0.200 |
Why?
|
| Normal Distribution | 1 | 2022 | 6 | 0.200 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 27 | 0.190 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 98 | 0.190 |
Why?
|
| United States | 2 | 2024 | 2033 | 0.190 |
Why?
|
| Prognosis | 1 | 2023 | 758 | 0.190 |
Why?
|
| Rituximab | 1 | 2021 | 59 | 0.190 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 12 | 0.190 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 126 | 0.190 |
Why?
|
| Models, Theoretical | 1 | 2022 | 129 | 0.190 |
Why?
|
| Lymphoma, T-Cell | 1 | 2020 | 7 | 0.180 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 34 | 0.180 |
Why?
|
| Incidence | 2 | 2019 | 545 | 0.180 |
Why?
|
| Retrospective Studies | 3 | 2021 | 2436 | 0.180 |
Why?
|
| Etoposide | 1 | 2020 | 19 | 0.180 |
Why?
|
| Biological Products | 1 | 2021 | 60 | 0.180 |
Why?
|
| Heart | 1 | 2021 | 219 | 0.170 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 11 | 0.170 |
Why?
|
| Secondary Prevention | 1 | 2020 | 45 | 0.170 |
Why?
|
| Pheochromocytoma | 1 | 2019 | 9 | 0.160 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2019 | 15 | 0.160 |
Why?
|
| Cohort Studies | 1 | 2021 | 858 | 0.160 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 275 | 0.160 |
Why?
|
| Survivors | 1 | 2019 | 36 | 0.160 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 398 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 122 | 0.160 |
Why?
|
| Adolescent | 2 | 2023 | 2954 | 0.160 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 1924 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2020 | 2262 | 0.140 |
Why?
|
| Adult | 3 | 2023 | 7360 | 0.130 |
Why?
|
| Bibliometrics | 1 | 2015 | 19 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 339 | 0.120 |
Why?
|
| Smoking | 1 | 2018 | 465 | 0.120 |
Why?
|
| Middle Aged | 2 | 2023 | 6797 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2015 | 93 | 0.110 |
Why?
|
| Neoplasms | 1 | 2022 | 748 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 346 | 0.090 |
Why?
|
| Female | 3 | 2023 | 14418 | 0.090 |
Why?
|
| Male | 2 | 2023 | 12834 | 0.090 |
Why?
|
| Animals | 1 | 2021 | 9921 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2023 | 41 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cladribine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Pharmacovigilance | 1 | 2022 | 3 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Azacitidine | 1 | 2022 | 8 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2022 | 7 | 0.050 |
Why?
|
| Triazines | 1 | 2022 | 11 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 51 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 14 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 43 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 26 | 0.050 |
Why?
|
| Comorbidity | 1 | 2023 | 251 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 42 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 218 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2022 | 68 | 0.050 |
Why?
|
| Bortezomib | 1 | 2021 | 18 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 31 | 0.050 |
Why?
|
| Hospitalization | 1 | 2023 | 192 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 177 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2021 | 52 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 61 | 0.040 |
Why?
|
| Catecholamines | 1 | 2019 | 18 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 134 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 143 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 84 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 274 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 225 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 145 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 407 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 445 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 714 | 0.030 |
Why?
|
| Middle East | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 818 | 0.030 |
Why?
|